AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8848916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IT‐IM and IT)
Number of subjects: 20
Study 8848916 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal (0.4 mg) morphine (IT‐group)
Number of subjects: 20
Study 1325325 — intervention group
Group type: COMPARATOR
Intervention: Low calcium diet
Number of subjects: 10
Study 1325325 — intervention group
Group type: COMPARATOR
Intervention: High calcium diet
Number of subjects: 10
Study 1325325 — intervention group
Group type: COMPARATOR
Intervention: Water restriction
Number of subjects: 10
Study 1325325 — intervention group
Group type: COMPARATOR
Intervention: Water diuresis
Number of subjects: 10
Study 6438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IF) at 1.8 g/m2 days 1‐5 q 4 weeks with Mesna (0.36 g/m2 i.v. or 0.72 g/m2 orally) given after each IF injection.
Number of subjects: 36
Study 6438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna uroprotection
Number of subjects: 36
Study 6438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IF)
Number of subjects: 36
Study 6438851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide + Mesna combination
Number of subjects: 36
Study 30967589 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT)
Number of subjects: 19
Study 30967589 — intervention group
Group type: COMPARATOR
Intervention: Control therapy sessions
Number of subjects: 19
Study 30186869 — intervention group
Group type: EXPERIMENTAL
Intervention: Boer formula
Number of subjects: 55
Study 30186869 — intervention group
Group type: COMPARATOR
Intervention: James formula
Number of subjects: 55
Study 26803431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) at 85-90% of peak heart rate three times/week for 12 weeks
Number of subjects: 70
Study 26803431 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet (LED, 800-1000 kcal/day) for 8-10 weeks followed by 2-4 weeks' weight maintenance diet
Number of subjects: 70
Study 24472270 — intervention group
Group type: EXPERIMENTAL
Intervention: 5° laterally elevated wedged insoles (group A)
Number of subjects: 118
Study 24472270 — intervention group
Group type: COMPARATOR
Intervention: Neutrally wedged insoles (group B)
Number of subjects: 118
Study 20661086 — intervention group
Group type: EXPERIMENTAL
Intervention: MBAC/AWBF
Number of subjects: 191
Study 20661086 — intervention group
Group type: COMPARATOR
Intervention: N-MBAC/AWBF
Number of subjects: 191
Study 17445128 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 91
Study 17445128 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (Control)
Number of subjects: 91
Study 17445128 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC) and Immediate cord clamping (Control)
Number of subjects: 91
Study 15543327 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA) and general anesthesia (GA) combined (Group EA/GA)
Number of subjects: 19
Study 15543327 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) alone (Group GA)
Number of subjects: 19
Study 12039990 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D (0.25 microg/d) plus calcium (1000 mg/d)
Number of subjects: 111
Study 12039990 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NoT group)
Number of subjects: 111
Study 9682957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface treated catheters (SPI-ARGENT, Spire Corporation, Bedford, MA)
Number of subjects: 122
Study 9682957 — intervention group
Group type: COMPARATOR
Intervention: Untreated catheters
Number of subjects: 122
Study 9682957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface treated catheters
Number of subjects: 122
Study 7981510 — intervention group
Group type: EXPERIMENTAL
Intervention: Superparamagnetic iron oxide (SHU 555 A) at doses of 5, 10, 20, and 40 mumol/kg
Number of subjects: 32
Study 7981510 — intervention group
Group type: EXPERIMENTAL
Intervention: Superparamagnetic iron oxide (SHU 555 A)
Number of subjects: 32
Study 2689345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g i.v. bolus t.i.d. for a mean of 8.2 days)
Number of subjects: 62
Study 2689345 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g i.v. bolus t.i.d. for a mean of 8.2 days)
Number of subjects: 62
Study 31187152 — intervention group
Group type: COMPARATOR
Intervention: IV THC (0.05 mg/kg)
Number of subjects: 74
Study 31187152 — intervention group
Group type: COMPARATOR
Intervention: Tolcapone (200 mg) followed by IV THC
Number of subjects: 74
Study 31187152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 74
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (arm A)
Number of subjects: 206
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiochemotherapy (Cap 50: 50 Gy irradiation and 1600 mg/m oral capecitabine daily) plus surgery (arm B)
Number of subjects: 206
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap 50 (arm C)
Number of subjects: 206
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive radiochemotherapy (Cap 60, 60 Gy irradiation, arm D)
Number of subjects: 206
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap 50 and Cap 60 (arms C and D)
Number of subjects: 206
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential resection margin ≤1 rates
Number of subjects: 206
Study 28594714 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformation from positive to negative circumferential resection margin
Number of subjects: 206
Study 25268043 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 25268043 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0
Study 25268043 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 0
Study 25268043 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 24075767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 169
Study 24075767 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with olive oil
Number of subjects: 169
Study 21350408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (infusion solution) prescribed in the first 2‐4 hours after delivery to 61 newborns
Number of subjects: 120
Study 21350408 — intervention group
Group type: COMPARATOR
Intervention: Control group (59 newborns who did not receive the drug)
Number of subjects: 120
Study 19298567 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LBBB present in 246 (2.6%) patients
Number of subjects: 9541
Study 19298567 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RBBB present in 428 (4.5%) patients
Number of subjects: 9541
Study 17253066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel (10cc)
Number of subjects: 44
Study 17253066 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic lidocaine injection (1% in 10cc)
Number of subjects: 44
Study 14587264 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose given at least 6 hours before PCI
Number of subjects: 0
Study 14587264 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily after PCI
Number of subjects: 0
Study 14587264 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the loading dose of clopidogrel if intervention must be undertaken sooner
Number of subjects: 0
Study 10893283 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (G + V)
Number of subjects: 120
Study 10893283 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine alone (V)
Number of subjects: 120
Study 8770129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil diameter measurements
Number of subjects: 24
Study 8770129 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpebral fissure measurements
Number of subjects: 24
Study 8770129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 24
Study 1579323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic treatment with 2 mg of estradiol valerate for 3 weeks + 250 micrograms of levonorgestrel for the last 10 days
Number of subjects: 40
Study 1579323 — intervention group
Group type: COMPARATOR
Intervention: 20-micrograms/24-hour levonorgestrel-releasing intrauterine device (IUD) + 2 mg of estradiol valerate daily
Number of subjects: 40
Study 1579323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Cyclic treatment and IUD)
Number of subjects: 40
Study 1579323 — intervention group
Group type: COMPARATOR
Intervention: IUD group
Number of subjects: 40
Study 4044854 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 12
Study 4044854 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training
Number of subjects: 12
Study 4044854 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined (Biofeedback and Video game)
Number of subjects: 12
Study 4044854 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment controls (Institutionalized residents)
Number of subjects: 12
Study 4044854 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment controls (Staff counselors)
Number of subjects: 12
Study 3553048 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 3553048 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0
Study 31854463 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder block (20 ml bupivacaine 0.5%)
Number of subjects: 30
Study 31854463 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder block
Number of subjects: 30
Study 31854463 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (20 ml bupivacaine 0.5%)
Number of subjects: 30
Study 31854463 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 30
Study 29921529 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mA left-DLPFC anodal tDCS
Number of subjects: 22
Study 29921529 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-DLPFC cathodal tDCS
Number of subjects: 22
Study 29921529 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 26804105 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based employability intervention
Number of subjects: 63
Study 26804105 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 26065432 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (2 mA, 35 cm², for 20 minutes, 5 sessions)
Number of subjects: 17
Study 26065432 — intervention group
Group type: COMPARATOR
Intervention: Sham-transcranial direct current stimulation (placebo)
Number of subjects: 17
Study 24355241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of hyaluronic acid (HA) using Ialumar® nasal spray for 30 days
Number of subjects: 59
Study 24355241 — intervention group
Group type: COMPARATOR
Intervention: Physiological solution (control group) for 30 days
Number of subjects: 59
Study 21914589 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) adjunctive therapy, dosage of 244.8 ± 108 mg/d at study end
Number of subjects: 207
Study 21914589 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) adjunctive therapy
Number of subjects: 207
Study 18946826 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based animations
Number of subjects: 0
Study 18946826 — intervention group
Group type: COMPARATOR
Intervention: Static graphics
Number of subjects: 0
Study 17219526 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education plus the educational intervention (two small-group, case-based discussions on acute dyspnea management)
Number of subjects: 26
Study 17219526 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 26
Study 17219526 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education plus the educational intervention (per-protocol analysis)
Number of subjects: 26
Study 17219526 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education plus the educational intervention
Number of subjects: 26
Study 14607015 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional paracetamol tablets (1,500 mg) with morphine (10 mg 4 hourly for 12 hours prior)
Number of subjects: 2
Study 14607015 — intervention group
Group type: COMPARATOR
Intervention: Conventional paracetamol tablets (1,500 mg) without morphine
Number of subjects: 2
Study 14607015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible paracetamol tablets (1,500 mg) with morphine (10 mg 4 hourly for 12 hours prior)
Number of subjects: 2
Study 14607015 — intervention group
Group type: COMPARATOR
Intervention: Dispersible paracetamol tablets (1,500 mg) without morphine
Number of subjects: 2
Study 11004039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hypobaric lidocaine 50 mg (Group L50)
Number of subjects: 110
Study 11004039 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hypobaric lidocaine 20 mg + 25 microg fentanyl (Group L20/F25)
Number of subjects: 110
Study 8625683 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. milrinone lactate
Number of subjects: 12
Study 8625683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1475810 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria chemoprophylaxis during pregnancy
Number of subjects: 0
Study 6364997 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 30
Study 6364997 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 30
Study 31733786 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training together with traditional treatment
Number of subjects: 20
Study 31733786 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 20
Study 29967446 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal individuals synchronised with their closest neighbour
Number of subjects: 0
Study 29967446 — intervention group
Group type: COMPARATOR
Intervention: Focal individuals not synchronised with their closest neighbour
Number of subjects: 0
Study 27495291 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 27495291 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0
Study 27495291 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (6-8 mg)
Number of subjects: 0
Study 27495291 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg and 300 mg)
Number of subjects: 0
Study 27495291 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 25064721 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC (brinzolamide 1% and brimonidine 0.2%)
Number of subjects: 560
Study 25064721 — intervention group
Group type: COMPARATOR
Intervention: brinzolamide 1%
Number of subjects: 560
Study 25064721 — intervention group
Group type: COMPARATOR
Intervention: brimonidine 0.2%
Number of subjects: 560
Study 22377820 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 154
Study 22377820 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 154
Study 20132586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil diet (mean beta-carotene intake 3.1 mg/d)
Number of subjects: 17
Study 20132586 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet (mean beta-carotene intake 7.6 mg/d)
Number of subjects: 17
Study 17714824 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide/Metformin/NPH (Group A)
Number of subjects: 37
Study 17714824 — intervention group
Group type: COMPARATOR
Intervention: Metformin/NPH (Group B)
Number of subjects: 37
Study 17714824 — intervention group
Group type: COMPARATOR
Intervention: NPH/NPH (Group C)
Number of subjects: 37
Study 15877556 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary program of geriatric consultation, continuous rehabilitation, and discharge planning
Number of subjects: 137
Study 11967679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous before extubation
Number of subjects: 68
Study 11967679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 68
Study 11967679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 9579009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, healthy-weight intervention (18 pamphlets mailed over 8 weeks)
Number of subjects: 188
Study 9579009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 188
Study 8617529 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 108
Study 8617529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 108
Study 2750831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and episcleral sponges
Number of subjects: 175
Study 2750831 — intervention group
Group type: COMPARATOR
Intervention: Diathermy, scleral dissection, and encircling silicone bands
Number of subjects: 175
Study 371319 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic bowel preparation for 24 hours
Number of subjects: 0
Study 371319 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic bowel preparation for 60 hours
Number of subjects: 0
Study 371319 — intervention group
Group type: COMPARATOR
Intervention: Preoperative antibiotic bowel preparation (both 24 and 60 hours)
Number of subjects: 0
Study 31609189 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 0
Study 31609189 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 31609189 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 31609189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 31609189 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injection formulations of SGAs
Number of subjects: 0
Study 31302964 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-TAMIS-GP
Number of subjects: 67
Study 31302964 — intervention group
Group type: COMPARATOR
Intervention: ESD
Number of subjects: 67
Study 30400965 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid replacement therapy
Number of subjects: 148
Study 30400965 — intervention group
Group type: COMPARATOR
Intervention: General opioid dependent patients using substance use disorder services
Number of subjects: 148
Study 28107141 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery by conventional means (group B)
Number of subjects: 151
Study 28107141 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with microdebrider (group C)
Number of subjects: 151
Study 28107141 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgically treated (group A)
Number of subjects: 151
Study 24029470 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-servo ventilation (ASV)
Number of subjects: 32
Study 24029470 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment (control)
Number of subjects: 32
Study 22681932 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised O&M-training
Number of subjects: 68
Study 22681932 — intervention group
Group type: COMPARATOR
Intervention: Regular O&M-training
Number of subjects: 68
Study 19101663 — intervention group
Group type: EXPERIMENTAL
Intervention: Notebook computer accessories
Number of subjects: 289
Study 19101663 — intervention group
Group type: EXPERIMENTAL
Intervention: Notebook computer accessories and participatory ergonomics training
Number of subjects: 289
Study 19101663 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-survey rest breaks
Number of subjects: 289
Study 19101663 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported computer usage
Number of subjects: 289
Study 17484179 — intervention group
Group type: EXPERIMENTAL
Intervention: DCR
Number of subjects: 28
Study 17484179 — intervention group
Group type: EXPERIMENTAL
Intervention: Song's polyurethane stent
Number of subjects: 28
Study 15305249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL
Number of subjects: 93
Study 15305249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/mL
Number of subjects: 93
Study 15305249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/mL
Number of subjects: 93
Study 15305249 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 93
Study 12191848 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 microg daily for 12 months
Number of subjects: 567
Study 12191848 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal norethisterone acetate (NETA) continuously (170 or 350 microg/day)
Number of subjects: 567
Study 12191848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential oral NETA (1 mg/day)
Number of subjects: 567
Study 12191848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (20 mg/day)
Number of subjects: 567
Study 12191848 — intervention group
Group type: COMPARATOR
Intervention: British women
Number of subjects: 567
Study 9389846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 48
Study 9389846 — intervention group
Group type: COMPARATOR
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 48
Study 7946856 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (group 1, n = 11)
Number of subjects: 30
Study 7946856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and adrenaline (group 2, n = 11)
Number of subjects: 30
Study 7946856 — intervention group
Group type: COMPARATOR
Intervention: Neither hydrocortisone nor adrenaline (group 3, n = 8)
Number of subjects: 30
Study 3428285 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole pretreatment for a minimum of three months before 131I therapy
Number of subjects: 24
Study 3428285 — intervention group
Group type: COMPARATOR
Intervention: 131I therapy alone
Number of subjects: 24
Study 29605187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 75